Post Reply
3841-3860 of 10899
DBS Vickers has initiate coverage on Biosensors, with a target price of 1.20
For info. Not a call to buy/sell.
topdog22 ( Date: 15-Sep-2010 05:15) Posted:
|
allright ( Date: 16-Sep-2010 09:44) Posted:
|
lostbell ( Date: 16-Sep-2010 07:58) Posted:
|
Biosensors Awarded CE Mark For Longer Lengths Of BioMatrix Flex Drug-Eluting Stent
Biosensors International Group, Ltd. (“Biosensors” or the “Company”, Bloomberg: BIG SP) announced today that it has received CE Mark approval for both 33mm and 36mm lengths of its BioMatrix Flex™ drug-eluting stent (DES) system, further expanding the currently available range of 8mm to 28mm lengths. Both longer lengths of stent are available in diameters ranging from 2.50mm to 3.50mm.
waiting for:
1) HK pricing on Microport Sept 17th trading begins the 24th. Microport gross revenue est for current year about 100M last year about 80M Pricing at hi end of rang give value of about $1B or about 10 times expected reveune. BIG expected revenue for this year about 140M.
2) TCT news Sept 21-23.
3) BIG 2nd qtr earning October
4) Mkt Clearance for China
Any or all of these catalyst for next leg up
minotaur ( Date: 09-Sep-2010 22:33) Posted:
|
finally, this gem is moving steadily uptrends... have been monitoring its movement pattern in chart... congrats to all those who are still holding it :) let us all HUAT $$$! happy trading!
derekloh ( Date: 08-Sep-2010 13:03) Posted:
|
Listing date for Microport Scientific Cop, will be 24 Sep.
TCT 2010
Tuesday 21st September:
The Drug-Eluting Stent Summit (Part 1) – 3:29 AM – Ballroom C
BioMatrix: First Report from the Three Year LEADERS TRIAL
Patrick W. Serruys
Wednesday 22nd September:
The Drug-Eluting Stent Summit (Part 2) – 10:32 AM – Ballroom C
Biolimus A9 Elution from a Micro-Structured Surface-Modified Stent:
The BioFreedom Stent and FIM Trial
Eberhard Grube
Oral Abstract Sessions – 4:15 PM – TCT-36
LEADERS: Three-Year Follow-up from a Prospective, Randomized
Trial of Biolimus A9-Eluting Stents with a Bioabsorbable Polymer vs. Sirolimus-Eluting Stents with a Durable Polymer
Patrick W. Serruys
Poster Abstract Sessions – 1:00-3:30 PM – TCT-233
Comparison of Polymer-Free BioFreedom™ Stents with
Polymer-Based TAXUS® Liberte Stents: The Four-MonthIntravascular Ultrasound Results from the Biofreedom First-in-Man Trial
Hiromasa Otake et al
Special Twilight Sessions – 6:00 PM – Room 140A
LEADERS: Three-Year Follow-up from a Prospective Randomized Trial
of Biolimus A9-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease - Featured Clinical Research II
Patrick W. Serruys
Evening Symposium sponsored by Biosensors:
Thursday 23rd September:
7:00-9:30 PM – Grand Hyatt Washington, Independence Ballroom
"New Insights into the LEADERS trial"
From a DES to a BMS – BA9™ Technology
Improving Long Term Patient Outcomes.
biosensors actually breakout from a ascending triangle yesterday!
support @ $0.83
Target @ $0.96
good luck
|
Biosensors International BIG SP
BUY NOMURA SINGAPORE LIMITED COMPANY QUICK COMMENT According to Bloomberg, Microport Scientific, the leader in the Chinese drug-eluting stent market, is raising about US$150mn via a Hong Kong IPO this month (Bloomberg, 1 Sep 2010). If Weigao's current valuation of 35x FY11 P/E is any guide for Microport's, we believe a successful IPO by Microport could be a re-rating catalyst for Biosensors, which owns 50% of JWMS - the last remaining private stent maker in China with a significant market share. Reiterate BUY -- we'll provide further industry analysis on Microport's prospectus pending its release. |
|
Price target: SGD 1.2 Price (03 Sep 2010): SGD 0.81 Research analyst: Jit Soon Lim 65.6433.6969 jitsoon.lim@nomura.com Research analyst: Yuan Yiu Tsai 65-6433-6964 yuanyiu.tsai@nomura.com ublish Date: 06 Sep 2010 P Peer listing to drive rerating? Market leader with first mover's advantage. Microport is the market leader in drug-eluting stents (DES) in China with a c30% market share (vs. 20~25% for Lepu and JWMS). Its DES Firebird was the first local DES to be launched in China (in May 2004). While we believe its technology is not groundbreaking (sirolimus-eluting stent similar to Johnson & Johnson's Cypher), Firebird has maintained its market-leading status over the years due to its first mover advantage, albeit with a declining market share. It has recently launched a clinical trial for a next-generation DES FIREHAWK which has a biodegradable polymer. (for more details, see our initiation report Moving past the inflexion point, 16 Oct 2009)Re-rating of Biosensors? One part of the investor feedback we have received on BIG is the lack of a trading comparable (ie, a single-product cardiovascular device company listed in Asia, excluding A-shares). Therefore we believe Microport's H-shares listing augers well for BIG as investors potentially become more knowledgeable on the industry. If Weigao's current valuation of 35x FY11F P/E is any guide for Microport's listing, we believe a successful IPO by Microport could be a re-rating catalyst for Biosensors, which owns 50% of JWMS. Our PT of $1.20 values JWMS at 22x FY10F P/E.We will provide further analysis pending the release of Microport's IPO prospectus. |